I received my Ph.D. in Basic Medicine from Wuhan University and have over 10 years of research experience in cancer biology. During my postdoctoral training at Northwestern University, I discovered that the splicing factor SF3B1 is posttranslationally regulated in T-cell acute lymphoblastic leukemia (T-ALL) and demonstrated the therapeutic potential of targeting splicing components—findings published in high-impact journals. Currently, I am a associate research scientist at The Jackson Laboratory, where I investigate mechanisms of drug resistance in acute myeloid leukemia (AML), with a focus on how the isoform-specific transcription factor RUNX1C contributes to chemotherapy resistance. My research leverages CRISPR-based functional screens and in vivo leukemia models to identify novel therapeutic strategies.
